XML 56 R38.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT REPORTING (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of financial information by reportable segments | Financial information by reportable segment is as follows:
|  | Three Months Ended September 30, 2025
|  | Generics and Other |  | Rare Disease and Brands |  | Corporate and Unallocated |  | Total
Net Revenues |  | $ | 98,688 |  | $ | 129,125 |  | $ | — |  |  | $ | 227,813 |
Less: |  |  |  |  |  |  |  |
Cost of sales (excluding depreciation and amortization) |  | 53,736 |  |  | 39,653 |  |  | — |  |  | 93,389 |
Research and development |  | 8,472 |  |  | 3,832 |  |  | — |  |  | 12,304 |
Selling, general, and administrative |  | 1,405 |  |  | 43,983 |  |  | 31,268 |  |  | 76,656 |
Depreciation and amortization |  | — |  |  | — |  |  | 22,632 |  |  | 22,632 |
Contingent consideration fair value adjustment |  | — |  |  | — |  |  | (14,470) |  |  | (14,470) |
Loss on disposal of assets |  | — |  |  | — |  |  | 295 |  |  | 295 |
Intangible asset impairment charge |  | — |  |  | — |  |  | 767 |  |  | 767 |
Operating Income (Loss) |  | $ | 35,075 |  |  | $ | 41,657 |  |  | $ | (40,492) |  |  | $ | 36,240 |
Unrealized gain on investment in equity securities |  | $ | — |  |  | $ | — |  |  | $ | 3,140 |  |  | $ | 3,140 |
Interest expense, net |  | — |  |  | — |  |  | (4,727) |  |  | (4,727) |
Other expense, net |  | — |  |  | — |  |  | (853) |  |  | (853) |
Income (Loss) Before Income Tax Expense |  | $ | 35,075 |  |  | $ | 41,657 |  |  | $ | (42,932) |  |  | $ | 33,800 |
|  | Three Months Ended September 30, 2024
|  | Generics and Other |  | Rare Disease and Brands |  | Corporate and Unallocated |  | Total
Net Revenues |  | $ | 82,711 |  | $ | 65,621 |  | $ | — |  |  | $ | 148,332 |
Less: |  |  |  |  |  |  |  |
Cost of sales (excluding depreciation and amortization) |  | 42,585 |  |  | 20,490 |  |  | — |  |  | 63,075 |
Research and development |  | 6,123 |  |  | 4,005 |  |  | — |  |  | 10,128 |
Selling, general, and administrative |  | 1,384 |  |  | 35,705 |  |  | 41,986 |  |  | 79,075 |
Depreciation and amortization |  | — |  |  | — |  |  | 15,748 |  |  | 15,748 |
Contingent consideration fair value adjustment |  | — |  |  | — |  |  | 825 |  |  | 825 |
Operating (Loss) Income |  | $ | 32,619 |  | $ | 5,421 |  | $ | (58,559) |  | $ | (20,519)
Unrealized gain on investment in equity securities |  | $ | — |  |  | $ | — |  |  | $ | 1,355 |  |  | $ | 1,355 |
Interest expense, net |  | — |  |  | — |  |  | (2,331) |  |  | (2,331) |
Other expense, net |  | — |  |  | — |  |  | (2,535) |  |  | (2,535) |
Loss on extinguishment of debt |  | — |  | — |  | (7,468) |  |  | (7,468) |
Income (Loss) Before Income Tax Benefit |  | $ | 32,619 |  | $ | 5,421 |  | $ | (69,538) |  |  | $ | (31,498) |
|  | Nine Months Ended September 30, 2025
|  | Generics and Other |  | Rare Disease and Brands |  | Corporate and Unallocated |  | Total
Net Revenues |  | $ | 295,941 |  | $ | 340,365 |  | $ | — |  |  | $ | 636,306 |
Less: |  |  |  |  |  |  |  |
Cost of sales (excluding depreciation and amortization) |  | 143,468 |  |  | 97,573 |  |  | — |  |  | 241,041 |
Research and development |  | 26,474 |  |  | 12,929 |  |  | — |  |  | 39,403 |
Selling, general, and administrative |  | 4,202 |  |  | 137,610 |  |  | 93,143 |  |  | 234,955 |
Depreciation and amortization |  | — |  |  | — |  |  | 68,804 |  |  | 68,804 |
Contingent consideration fair value adjustment |  | — |  |  | — |  |  | (25,285) |  |  | (25,285) |
Loss on disposal of assets |  | — |  |  | — |  |  | 295 |  |  | 295 |
Intangible asset impairment charge |  | — |  |  | — |  |  | 767 |  |  | 767 |
Operating Income (Loss) |  | $ | 121,797 |  | $ | 92,253 |  | $ | (137,724) |  | $ | 76,326
Unrealized gain on investment in equity securities |  | $ | — |  |  | $ | — |  |  | $ | 2,551 |  |  | $ | 2,551 |
Interest expense, net |  | — |  |  | — |  |  | (15,649) |  |  | (15,649) |
Other income, net |  | — |  |  | — |  |  | 1,084 |  |  | 1,084 |
Income (Loss) Before Income Tax Expense |  | $ | 121,797 |  | $ | 92,253 |  | $ | (149,738) |  |  | $ | 64,312 |
|  | Nine Months Ended September 30, 2024
|  | Generics and Other |  | Rare Disease and Brands |  | Corporate and Unallocated |  | Total
Net Revenues |  | $ | 236,346 |  | $ | 187,456 |  | $ | — |  |  | $ | 423,802 |
Less: |  |  |  |  |  |  |  |
Cost of sales (excluding depreciation and amortization) |  | 121,399 |  |  | 48,531 |  |  | — |  |  | 169,930 |
Research and development |  | 19,569 |  |  | 8,366 |  |  | — |  |  | 27,935 |
Selling, general, and administrative |  | 3,737 |  |  | 86,720 |  |  | 89,460 |  |  | 179,917 |
Depreciation and amortization |  | — |  |  | — |  |  | 45,131 |  |  | 45,131 |
Contingent consideration fair value adjustment |  | — |  |  | — |  |  | 1,274 |  |  | 1,274 |
Gain on sale of building |  | — |  |  | — |  |  | (5,347) |  |  | (5,347) |
Operating Income (Loss) |  | $ | 91,641 |  | $ | 43,839 |  | $ | (130,518) |  | $ | 4,962
Unrealized gain on investment in equity securities |  | $ | — |  |  | $ | — |  |  | $ | 8,298 |  |  | $ | 8,298 |
Interest expense, net |  | — |  |  | — |  |  | (11,587) |  |  | (11,587) |
Other expense, net |  | — |  |  | — |  |  | (2,655) |  |  | (2,655) |
Loss on extinguishment of debt |  | — |  | — |  | (7,468) |  |  | (7,468) |
Income (Loss) Before Income Tax Benefit |  | $ | 91,641 |  | $ | 43,839 |  | $ | (143,930) |  |  | $ | (8,450) |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration